Newsroom 2006
Attention Business/Financial Editors:
Neurochem to Report on Third Quarter of Fiscal 2006
Neurochem will host a conference call Thursday, November 9, 2006,
at 8:30 A.M. ET
LAVAL, QC, Nov. 7 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announces that it will release its results for the third quarter of fiscal
2006, ended September 30, tomorrow, after market close.
The Company will host a conference call at 8:30 A.M. ET, on Thursday,
November 9, 2006. During the conference call, Dr. Francesco Bellini, Chairman,
President and Chief Executive Officer, Mr. Mariano Rodriguez, Vice President,
Finance and Chief Financial Officer, and Dr. Denis Garceau, Senior Vice
President, Drug Development will present Neurochem's overall strategy and
progress to date, together with the highlights of its financial results.
To participate in the conference call, please dial the following numbers
approximately 10 minutes prior to the start of the call: 416-644-3426 or
1-866-249-2157. A replay of the conference call will be available for one week
(until November 16, 2006), commencing one hour after the end of the call. The
instant replay numbers are 416-640-1917 or 1-877-289-8525, passcode
21208556(pound key). Please mention that you are calling for the Neurochem
conference replay.
About Neurochem
Neurochem Inc. is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(KIACTA(TM); formerly FIBRILLEX(TM)) is currently being developed for the
treatment of AA amyloidosis, and is under regulatory review for marketing
approval by the U.S. Food and Drug Administration and European Medicines
Agency. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease,
is currently in Phase III clinical trials in both North America and Europe and
tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused
by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1-877-680-4500 or
visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, as well as other risks
disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Neurochem is under no obligation
and disavows any intention to update or revise such statements as a result of
any event, circumstances or otherwise. Please see the Annual Information Form
for further risk factors that might affect the Company and its business.
For further information: Lise Hébert, PhD, Vice President, Corporate
Communications, (450) 680-4570, lhebert@neurochem.com
